Giorgia Giordano

Dr. Giorgia Giordano


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 February 2025 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
ASAurora Schiavon
Aurora Schiavon
LSLaura Saba
Laura Saba
CECarlotta Evaristo
Carlotta Evaristo
Jessica PetitiJessica Petiti
Jessica Petiti
Ymera PignochinoYmera Pignochino
Ymera Pignochino
MIMarco Lo Iacono
Marco Lo Iacono
Adrenocortical Carcinoma is a rare and aggressive endocrine malignancy, that arises from cells of one of the three cortical layers of the adrenal gland. Radical surgery is the only curative treatment, even if recurrence rates are high. Therapeutic options are limited, with mitotane as the cornerstone of medical therapy. Despite 50 years of clinical use, the mechanism of action of mitotane has not yet been fully established, possibly due to the drug's susceptibility to interaction with confounding factors that reduce its biological activity. In the present study, we evaluated by RNAseq the effect of mitotane on gene expression in the H295R cell line, in an environment free of known confounding factors. Our approach allowed us to identify transcriptional deregulation of the ATF4/ATF3 axis, often involved in ER stress. These results were also validated by ddPCR in independent experiments. Mitotane-mediated ATF4 overexpression was also confirmed at the protein level. We observed how an incremental concentration of mitotane could deregulate main biological pathways. Further, we confirmed, both at RNAseq and ddPCR level, the mitotane-mediated downmodulation of genes such as STAR, CYP11A1, CYP21A2, and HSD3B2, highlighting its effect on steroid hormones biosynthesis. Through our approach, we identified biological pathways altered by mitotane in early response stages and with low drug concentrations. Some of these pathways could potentially be investigated in the future as functional biomarkers to monitor adrenocortical carcinoma treatment or as new pharmacological targets for this rare disease.

Verified
Journal Article
Open access
PDF file
Jessica PetitiJessica Petiti
Jessica Petiti
Ymera PignochinoYmera Pignochino
Ymera Pignochino
ASAurora Schiavon
Aurora Schiavon
EGEmilia Giugliano
Emilia Giugliano
EBEnrico Berrino
Enrico Berrino
MIMarco Lo Iacono
Marco Lo Iacono
Acute myeloid leukemia (AML) is a complex hematologic malignancy with high morbidity and mortality. Nucleophosmin 1 (NPM1) mutations occur in approximately 30% of AML cases, and NPM1-mutated AML is classified as a distinct entity. NPM1-mutated AML patients without additional genetic abnormalities have a favorable prognosis. Despite this, 30–50% of them experience relapse. This study aimed to investigate the potential of total RNAseq in improving the characterization of NPM1-mutated AML patients. We explored genetic variations independently of myeloid stratification, revealing a complex molecular scenario. We showed that total RNAseq enables the uncovering of different genetic alterations and clonal subtypes, allowing for a comprehensive evaluation of the real expression of exome transcripts in leukemic clones and the identification of aberrant fusion transcripts. This characterization may enhance understanding and guide improved treatment strategies for NPM1mut AML patients, contributing to better outcomes. Our findings underscore the complexity of NPM1-mutated AML, supporting the incorporation of advanced technologies for precise risk stratification and personalized therapeutic strategies. The study provides a foundation for future investigations into the clinical implications of identified genetic variations and highlights the importance of evolving diagnostic approaches in leukemia management.

15 December 2021 in Cancers
Verified
Journal Article
Open access
PDF file
Ymera PignochinoYmera Pignochino
Ymera Pignochino
Giovanni CrisafulliGiovanni Crisafulli
Giovanni Crisafulli
GGGiorgia Giordano
Giorgia Giordano
AMAlessandra Merlini
Alessandra Merlini
EBEnrico Berrino
Enrico Berrino
GGGiovanni Grignani
Giovanni Grignani
Drug-induced tumor mutational burden (TMB) may contribute to unleashing the immune response in relatively “immune-cold” tumors, such as sarcomas. We previously showed that PARP1 inhibition perpetuates the DNA damage induced by the chemotherapeutic agent trabectedin in both preclinical models and sarcoma patients. In the present work, we explored acquired genetic changes in DNA repair genes, mutational signatures, and TMB in a translational platform composed of cell lines, xenografts, and tumor samples from patients treated with trabectedin and olaparib combination, compared to cells treated with temozolomide, an alkylating agent that induces hypermutation. Whole-exome and targeted panel sequencing data analyses revealed that three cycles of trabectedin and olaparib combination neither affected the mutational profiles, DNA repair gene status, or copy number alterations, nor increased TMB both in homologous recombinant-defective and proficient cells or in xenografts. Moreover, TMB was not increased in tumor specimens derived from trabectedin- and olaparib-treated patients (5–6 cycles) when compared to pre-treatment biopsies. Conversely, repeated treatments with temozolomide induced a massive TMB increase in the SJSA-1 osteosarcoma model. In conclusion, a trabectedin and olaparib combination did not show mutagenic effects and is unlikely to prime subsequent immune-therapeutic interventions based on TMB increase. On the other hand, these findings are reassuring in the increasing warning of treatment-induced hematologic malignancies correlated to PARP1 inhibitor use.

3 September 2026 in Cell Communication and Signaling
Verified
Journal Article
Open access
PDF file
GGGiorgia Giordano
Giorgia Giordano
CTCristina Tucciarello
Cristina Tucciarello
EGErika Gucciardo
Erika Gucciardo
JWJørgen Wesche
Jørgen Wesche
LMLeonardo A. Meza-Zepeda
Leonardo A. Meza-Zepeda
Ymera PignochinoYmera Pignochino
Ymera Pignochino
Background: Advanced osteosarcoma (OS) remains a clinical challenge due to its aggressive behavior and poor prognosis. Cancer-associated fibroblasts (CAFs) have been shown to contribute to tumor progression, but the tumor–CAF crosstalk in OS is still poorly defined. Elucidating these interactions could reveal novel therapeutic targets. Methods: Human OS surgical samples and cell lines were implanted into immunocompromised mice to generate 10 patient-derived (PDXs) and 10 cell line-derived xenografts (CDXs), respectively. RNA-sequencing was performed on the xenografts to distinguish murine stromal from human tumor transcripts. Stromal subpopulation metagenes and matched tumor-stroma ligand-receptor pairs were analyzed. The expression and roles of the candidate ligands were validated using histological analyses, RT-qPCR, Western blot, ELISA, proliferation, migration, invasion, sphere-forming, and RNA silencing assays. Their prognostic relevance was evaluated in human OS samples using a publicly available dataset with clinical annotations and by immunohistochemical analysis. Results: Stromal contribution and tumor growth varied across OS xenografts, with no significant differences between PDXs and CDXs. CAF, white blood cell, and endothelial cell metagenes correlated with stromal content, and myofibroblastic CAFs were the most prevalent subpopulation. The Ephrin A4-Epha2-Bmp4 axis was strongly associated with CAF content. Conditioned medium (CM) from OS cells, which can generate xenografts with high-CAF (HC) content, promoted normal fibroblast (NF) activation and CAF proliferation, migration, and invasion more than CM from low-CAF (LC) cells. Similar effects were observed upon direct treatment with soluble Ephrin A4, but not with CM from Ephrin A4-silenced HC OS cells. In turn, CAF-derived CM or direct treatment with soluble BMP4, but not the CM from BMP4-silenced CAFs, enhanced proliferation, migration, and invasion, and increased stem-like traits in HC OS cells. Ephrin A4 induced EphA2 expression in NFs and BMP4 production in CAFs, whereas BMP4 stimulated Ephrin A4 production in HC OS cells, establishing a tumor-stroma feed-forward loop. The co-expression of human Ephrin A4 and murine BMP4 mRNA was confirmed in HC OS xenografts. Tumor Ephrin A4 and stromal BMP4 were more highly expressed in HC human OS, characterized by higher stromal alpha-smooth muscle actin (αSMA) expression, as well as in OS patients with poor prognosis. Conclusion: Tumor-derived Ephrin A4 and stromal-derived BMP4 generate a feed-forward loop in OS, sustaining tumor aggressiveness. This axis represents a promising therapeutic target that warrants further translational investigations.